Cargando…

The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma

BACKGROUND: Programmed death-ligand 1 (PD-L1) is an important immune checkpoint inhibitor. Recent studies suggest that the PD-L1-mediated pathway may be a promising target in allergic asthma. However, the mechanism by which PD-L1 represses neutrophilic asthma (NA) remains unclear. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Yin-Ying, Dong, He-Ting, Liao, Jian-Yi, Sun, Hui-Ming, Wang, Ting, Gu, Wen-Jing, Zhang, Xin-Xing, Yan, Yong-Dong, Ji, Wei, Chen, Zheng-Rong, Zhu, Can-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743735/ https://www.ncbi.nlm.nih.gov/pubmed/35071421 http://dx.doi.org/10.21037/atm-21-5648

Ejemplares similares

The role of inducible costimulatory molecular ligand (ICOSL) in children with neutrophilic asthma
por: Dong, Heting, et al.
Publicado: (2020)

The Programmed Cell Death Ligand-1/Programmed Cell Death-1 Pathway Mediates Pregnancy-Induced Analgesia via Regulating Spinal Inflammatory Cytokines
por: Tan, HuiLing, et al.
Publicado: (2021)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis
por: McNab, Finlay W, et al.
Publicado: (2011)

The predictive role of soluble programmed death ligand 1 in digestive system cancers
por: Ruan, Jian, et al.
Publicado: (2023)

Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment
por: Li, Feng, et al.
Publicado: (2022)

Microbial Ligand Costimulation Drives Neutrophilic Steroid-Refractory Asthma
por: Hadebe, Sabelo, et al.
Publicado: (2015)

Programmed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics
por: Mou, Haibo, et al.
Publicado: (2021)

Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
por: Liao, Pei-Fei, et al.
Publicado: (2023)

Correction: Microbial Ligand Costimulation Drives Neutrophilic Steroid-Refractory Asthma
por: Hadebe, Sabelo, et al.
Publicado: (2015)

Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019)

Pathological significance of abnormal recepteur d’origine nantais and programmed death ligand 1 expression in colorectal cancer
por: Liu, Yi-Zhi, et al.
Publicado: (2020)

Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma
por: Li, Ying-Fei, et al.
Publicado: (2017)

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
por: Kim, Ji-Hyun, et al.
Publicado: (2019)

Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer
por: Lee, Jieun, et al.
Publicado: (2019)

Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas
por: Zeng, Jing, et al.
Publicado: (2016)

Programmed death-ligand 1 is upregulated in intrahepatic lymphoepithelioma-like cholangiocarcinoma
por: Wang, Lei, et al.
Publicado: (2016)

Programmed Death-Ligand 1 (PD-L1) Expression Associated with a High Neutrophil/Lymphocyte Ratio in Cholangiocarcinoma
por: Sangkhamanon, Sakkarn, et al.
Publicado: (2017)

Programmed death ligand 1 (PD-L1) expression in parathyroid tumors
por: Pan, Boju, et al.
Publicado: (2019)

Neutrophils and Asthma
por: Yamasaki, Akira, et al.
Publicado: (2022)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

In vitro neutrophil migration is associated with inhaled corticosteroid treatment and serum cytokines in pediatric asthma
por: Lemmel, Solveig, et al.
Publicado: (2022)

Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma
por: Song, Xing, et al.
Publicado: (2018)

Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma
por: Zheng, Lin-Lin, et al.
Publicado: (2021)

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
por: Zhao, Jing, et al.
Publicado: (2020)

Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
por: Sun, Xiaoying, et al.
Publicado: (2019)

Programmed death ligand 1 is overexpressed by neutrophils in the blood of immunocompromised human immunodeficiency virus-negative patients with Pneumocystis jirovecii pneumonia
por: Zhang, Nan-Nan, et al.
Publicado: (2019)

Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis
por: Deepak, H. B., et al.
Publicado: (2022)

Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors
por: Liu, Min, et al.
Publicado: (2020)

Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders
por: Zhao, Shangfeng, et al.
Publicado: (2014)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
por: Jaafar, Jaafar, et al.
Publicado: (2018)

Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
por: Yim, Nam-Hui, et al.
Publicado: (2020)

Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease
por: Goto, Hiroyuki, et al.
Publicado: (2021)

Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis
por: Zhou, Tingting, et al.
Publicado: (2018)

Suppressive effects of S100A8 and S100A9 on neutrophil apoptosis by cytokine release of human bronchial epithelial cells in asthma
por: Kim, Da Hye, et al.
Publicado: (2020)

The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes
por: Ding, Xing-Chen, et al.
Publicado: (2020)

Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy
por: Ha, Hyerim, et al.
Publicado: (2016)

Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro
por: Tay, Woan Ting, et al.
Publicado: (2020)

Effects of Macrolide and Corticosteroid in Neutrophilic Asthma Mouse Model
por: An, Tai Joon, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ethie13it9di3ciic5vu29f95n